ClinicalTrials.gg
CompletedNCT06039449Updated Dec 9, 2024

A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2

A Phase 3 interventional study of VYD222 (pemivibart) and Normal saline in COVID-19 and SARS-CoV-2, sponsored by Invivyd, Inc.. Completed at 18 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2024-12-09.

Sponsored by Invivyd, Inc. · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was Nov 2024, 2 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
790
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,860 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
244th of 1,322
790 · median 92
Started
2023
with 130 others
Phase 3
174 of 1,860
10 open now
Registered
1,697th of 1,860
by date

Among the 1,860 studies in COVID-19 with a site in United States, this one is the 244th largest by enrollment of the 1,322 interventional ones that give a count, is one of 131 that started in 2023, is one of 174 in phase 3, and was the 1,697th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,860 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,860 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

A study to investigate the prevention of COVID-19 with VYD222 in adults with immune compromise and in participants aged 12 years or older who are at risk of exposure to SARS-CoV-2

03

Conditions studied

  • COVID-19
  • SARS-CoV-2

Browse trials for

Keywords

  • Immune Compromise
  • VYD222
  • SARS-CoV-2 Monoclonal Antibody
  • COVID-19 Prevention
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is an adult aged ≥18 years or an adolescent aged 12 to \<18 years and weighs at least 40 kg at the time of Screening.
  • Tests negative for current SARS-CoV-2 infection by local antigen test or RT-PCR at the time of Screening.
  • For Cohort A, has significant immune compromise from causes including solid tumor or hematologic , chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic stem cell transplant, primary immunodeficiency, advanced infection, or receiving qualifying therapies.
  • For Cohort B, is at risk of acquiring SARS-CoV-2 due to regular unmasked face-to-face interactions in indoor settings.
  • Agrees to defer receipt of any COVID-19 vaccination or booster for a minimum of 28 days after dosing.
  • Note: unless specified by Cohort, the criteria apply to both Cohorts

Exclusion criteria

Exclusion Criteria:

  • For Cohort B: Prior receipt of a COVID-19 vaccine or booster within 120 days before randomization.
  • Prior receipt of convalescent plasma or a mAb to SARS-CoV-2 active against currently circulating variants, including in the setting of a clinical trial, within 120 days before randomization.
  • Prior known or suspected SARS-CoV-2 infection within 120 days before randomization.
  • Exposure to someone with known or suspected SARS-CoV-2 infection in the 5 days before randomization.
  • Is acutely ill or has any symptoms suggestive of infection, in the opinion of the Investigator.

Note 1: Other protocol defined inclusion/exclusion criteria apply Note 2: Unless specified by Cohort, the criteria apply to both Cohorts

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
790 participants (actual)

Study arms

  • Experimental
    Cohort A VYD222

    Drug: VYD222 (pemivibart)

  • Experimental
    Cohort B VYD222

    Drug: VYD222 (pemivibart)

  • Placebo comparator
    Cohort B Placebo

    Drug: Normal saline

Interventions

  • DrugVYD222 (pemivibart)

    Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with VYD222.

  • DrugNormal saline

    Participants will be dosed on Day 1 followed by redosing at Month 3 (approximately 90 days) with Placebo.

06

What researchers measure

Primary outcomes

  1. Cohort A - Incidence of treatment emergent adverse events

    Time frame: Through Month 12

  2. Cohort A - Ratio of SARS-CoV-2 sVNA titer against a relevant variant following VYD222 administration at Day 28 compared to a prespecified SARS-CoV-2 sVNA titer threshold.

    Time frame: Day 28

  3. Cohort B - Incidence of treatment emergent adverse events

    Time frame: Through Month 12

Secondary outcomes

  1. Cohort A - Proportion of participants with sVNA titer against a relevant variant following VYD222 administration at Day 28 above a prespecified SARS-CoV-2 sVNA titer threshold.

    Time frame: Day 28

  2. Cohort A - sVNA titer by timepoint following VYD222 administration

    Time frame: Through Month 12

  3. Cohort A - Proportion of participants with sVNA titer against a relevant variant following VYD222 administration above a minimum SARS-CoV-2 sVNA threshold by timepoint

    The minimum SARS-CoV-2 sVNA titer threshold will be prespecified prior to analysis.

    Time frame: Through Month 12

  4. Cohort A - ADAs against VYD222

    Time frame: Through Month 12

  5. Cohort A - Serum concentrations (PK) of VYD222

    Time frame: Through Month 12

  6. Cohort A - Proportion of participants with RT-PCR-confirmed symptomatic COVID-19

    RT-PCR-confirmed symptomatic COVID-19 is defined as RT-PCR-confirmed SARS-CoV-2 with an onset of symptoms occurring no more than 14 days from the date of the positive RT-PCR test sample collection, COVID-19-related hospitalization, or all-cause death.

    Time frame: Through Month 12

  7. Cohort B - Ratio of SARS-CoV-2 sVNA titer against a relevant variant following VYD222 administration at Day 28 compared to a prespecified SARS-CoV-2 sVNA titer threshold.

    Time frame: Day 28

  8. Cohort B - Proportion of participants with sVNA titer against a relevant variant following VYD222 administration at Day 28 above a prespecified SARS-CoV-2 sVNA titer threshold.

    Time frame: Day 28

  9. Cohort B - sVNA titer by timepoint following VYD222 administration

    Time frame: Through Month 12

  10. Cohort B - Proportion of participants with sVNA titer against a relevant variant following VYD222 administration above a minimum SARS-CoV-2 sVNA threshold by timepoint

    The minimum SARS-CoV-2 sVNA titer threshold will be prespecified prior to analysis.

    Time frame: Through Month 12

  11. Cohort B - COVID-19-related hospitalization or COVID-19-related death within 28 days of symptom onset

    Time frame: Through Month 12

  12. Cohort B - COVID-19-related death

    Time frame: Through Month 12

  13. Cohort B - Serum concentrations (PK) of VYD222

    Time frame: Through Month 12

  14. Cohort B - ADAs against VYD222

    Time frame: Through Month 12

07

Study locations

18 sites
  • INVIVYD Investigative Site
    Fullerton, California 92835, United States
  • INVIVYD Investigative Site
    Long Beach, California 90806, United States
  • INVIVYD Investigative Site
    Rolling Hills Estates, California 90274, United States
  • INVIVYD Investigative Site
    San Diego, California 92103, United States
  • INVIVYD Investigative Site
    Clearwater, Florida 33756, United States
  • INVIVYD Investigative Site
    Miami, Florida 33186, United States
  • INVIVYD Investigative Site
    St. Petersburg, Florida 33705, United States
  • INVIVYD Investigative Site
    Atlanta, Georgia 30328, United States
  • INVIVYD Investigative Site
    Hinesville, Georgia 31313, United States
  • INVIVYD Investigative Site
    Oak Brook, Illinois 60523, United States
  • INVIVYD Investigative Site
    Silver Spring, Maryland 20904, United States
  • INVIVYD Investigative Site
    Burlington, Massachusetts 01803, United States
  • INVIVYD Investigative Site
    Morrisville, North Carolina 27560, United States
  • INVIVYD Investigative Site
    Salisbury, North Carolina 28144, United States
  • INVIVYD Investigative Site
    Edmond, Oklahoma 73013, United States
  • INVIVYD Investigative Site
    Yukon, Oklahoma 73099, United States
  • INVIVYD Investigative Site
    Beaumont, Texas 77706, United States
  • INVIVYD Investigative Site
    Dallas, Texas 75230, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Nov 2024, 14 months.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 14 months is above that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2023
First posted
Sep 15, 2023
StartActual
Sep 8, 2023
Primary completionActual
Nov 19, 2024
CompletionActual
Nov 19, 2024
Last update
Dec 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06039449
Lead sponsor
Invivyd, Inc.
Responsible party
Sponsor
First posted
Sep 15, 2023
Start date
Sep 8, 2023
Primary completion
Nov 19, 2024
Completion
Nov 19, 2024
Last update
Dec 9, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion